ASpirin Use and stAtin Strategy for Primary Prevention in Severe Coronary Calcium Score on Computed Tomography

Официальное название

an Investigator-initiated, Multicenter, Open-label, 2-by-2 Factorial, and Randomized Trial to Evaluate the Role of Aspirin and High-intensity Statin Therapy, Respectively, in Individuals With Severe Coronary Calcification (Coronary Calcium Score ≥300) to Prevent Atherosclerotic Cardiovascular Disease (ASCVD) Events With Severe Coronary Calcification (CAC ≥300)

Обзор

The primary objective of the ASA-3C trial is to evaluate the role of aspirin and high-intensity statin therapy, respectively, in individuals with severe coronary calcification (coronary calcium score ≥300) to prevent atherosclerotic cardiovascular disease (ASCVD) events with severe coronary calcification (CAC ≥300).

Вмешательства

• Препарат Aspirin
  Patients will take aspirin 100 mg/day.
• Препарат High-intensity statin
  Statin intensity is defined according to the 2026 ACC/AHA Guideline on the Management of Dyslipidemia
• Препарат Guideline-directed statin therapy
  Statin intensity is defined according to the 2026 ACC/AHA Guideline on the Management of Dyslipidemia

Первичные конечные точки

• Event rate of a composite of atherosclerotic cardiovascular disease event [Срок оценки: 3 years]

Вторичные конечные точки (5)

• Event rate of Each individual component of primary composite outcome [Срок оценки: 3 years]
• Event rate of Death from any causes [Срок оценки: 3 years]
• Event rate of Hospitalization for heart failure [Срок оценки: 3 years]
• Event rate of the first occurrence of any major bleeding [Срок оценки: 3 years]
• Event rate of the Safety secondary endpoint [Срок оценки: 3 years]

Критерии участия

Критерии включения

• The subject must be aged between 40 and 75 years.
• Patients who have coronary artery calcium score ≥300 Agatston Unit on coronary calcium computed tomography.
• Patients who have 1 or more CVD risk factors in below;

• dyslipidemia or,
• diabetes or,
• hypertension or,
• family history of CVD or,
• smoking
• Patients agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Критерии исключения

• Individuals who have symptomatic coronary artery disease or heart failure.
• Patients who have documented clinical Atherosclerotic Cardiovascular Disease: previous myocardial infarction, acute coronary syndrome, stable angina, coronary revascularization and other arterial revascularization procedures, stroke and Transient ischaemic attack (TIA), >50% carotid stenosis or previous carotid endarterectomy or stenting, aortic aneurysm and peripheral artery disease.
• Patients who have evidence of myocardial ischemia on non-invasive stress test including stress single photon emission CT myocardial perfusion imaging (SPECT MPI), cardiovascular magnetic resonance (CMR) imaging, stress echocardiography, or treadmill test, or on invasive stress test including Fractional flow reserve (FFR) < 0.80 on invasive coronary angiography (diameter stenosis>50% without objective evidence of ischemia could be enrolled).
• Patients at high risk of bleeding: gastrointestinal hemorrhage or peptic ulcer within the previous 6 months; active hepatic disease such as cirrhosis or active hepatitis; use of warfarin, or other anticoagulant therapy; or has a history of aspirin allergy.
• Patients with atrial fibrillation and flutter.
• Patients with severe left ventricular dysfunction (ejection fraction ≤30%) or severe valvular heart disease who experience dyspnea on exertion (The NYHA (New York Heart Association) Functional Classification III-IV).
• History of allergy or severe adverse reaction to aspirin or statin or ezetimibe.
• History of myositis or myopathy with active disease in the 180 days prior to study entry.
• Patients with active liver disease or persistent unexplained serum transaminase elevation.
• Patients who have significantly abnormal findings which identified violation for safety by investigator on physical examination, blood test and electrocardiogram.
• History of alcohol or drug abuse.
• Concurrent medical condition with a life expectancy of less than 1 years.
• Pregnant and/or lactating women.
• Patient was unable to provide written informed consent or participate in log-term follow up.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Факторный дизайн

Маскирование

Открытое

Основная цель

Профилактика

Центры проведения

South Korea · 32 центра

• Hallym University Medical Center — Anyang
• SAM hospital — Anyang
• Sejong General Hospital — Bucheon-si
• Dong-A University Hospital — Busan
• Haeundae paik hospital, inje university — Busan
• Inje University Busan Paik Hospital — Busan
• Gyeongsang National University Changwon Hospital — Changwon
• Chungbuk National University Hospital — Cheonju
• … и ещё 24 центра

Идентификаторы

NCT: NCT06676280 · AMCCV 2024-01

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗